Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans

Abhinav Bhushan, Nina Senutovitch, Shyam S. Bale, William J. McCarty, Manjunath Hegde, Rohit Jindal, Inna Golberg, O. Berk Usta, Martin L. Yarmush, Lawrence Vernetti, Albert Gough, Ahmet Bakan, Tong Ying Shun, Richard Biasio, D. Lansing Taylor

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Although the process of drug development requires efficacy and toxicity testing in animals prior to human testing, animal models have limited ability to accurately predict human responses to xenobiotics and other insults. Societal pressures are also focusing on reduction of and, ultimately, replacement of animal testing. However, a variety of in vitro models, explored over the last decade, have not been powerful enough to replace animal models. New initiatives sponsored by several US federal agencies seek to address this problem by funding the development of physiologically relevant human organ models on microscopic chips. The eventual goal is to simulate a human-on-a-chip, by interconnecting the organ models, thereby replacing animal testing in drug discovery and development. As part of this initiative, we aim to build a three-dimensional human liver chip that mimics the acinus, the smallest functional unit of the liver, including its oxygen gradient. Our liver-on-a-chip platform will deliver a microfluidic three-dimensional co-culture environment with stable synthetic and enzymatic function for at least 4 weeks. Sentinel cells that contain fluorescent biosensors will be integrated into the chip to provide multiplexed, real-time readouts of key liver functions and pathology. We are also developing a database to manage experimental data and harness external information to interpret the multimodal data and create a predictive platform.

Original languageEnglish (US)
Article numberS16
JournalStem Cell Research and Therapy
Volume4
Issue numberSUPPL.1
DOIs
StatePublished - Dec 20 2013
Externally publishedYes

Fingerprint

Microfluidics
Drug-Related Side Effects and Adverse Reactions
Liver
Toxicity
Animals
Pharmaceutical Preparations
Testing
Animal Models
Biosensing Techniques
Pathology
Xenobiotics
Drug Discovery
Coculture Techniques
Biosensors
Databases
Oxygen
Pressure

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Molecular Medicine
  • Cell Biology
  • Medicine (miscellaneous)

Cite this

Bhushan, A., Senutovitch, N., Bale, S. S., McCarty, W. J., Hegde, M., Jindal, R., ... Lansing Taylor, D. (2013). Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans. Stem Cell Research and Therapy, 4(SUPPL.1), [S16]. https://doi.org/10.1186/scrt377

Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans. / Bhushan, Abhinav; Senutovitch, Nina; Bale, Shyam S.; McCarty, William J.; Hegde, Manjunath; Jindal, Rohit; Golberg, Inna; Berk Usta, O.; Yarmush, Martin L.; Vernetti, Lawrence; Gough, Albert; Bakan, Ahmet; Shun, Tong Ying; Biasio, Richard; Lansing Taylor, D.

In: Stem Cell Research and Therapy, Vol. 4, No. SUPPL.1, S16, 20.12.2013.

Research output: Contribution to journalArticle

Bhushan, A, Senutovitch, N, Bale, SS, McCarty, WJ, Hegde, M, Jindal, R, Golberg, I, Berk Usta, O, Yarmush, ML, Vernetti, L, Gough, A, Bakan, A, Shun, TY, Biasio, R & Lansing Taylor, D 2013, 'Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans', Stem Cell Research and Therapy, vol. 4, no. SUPPL.1, S16. https://doi.org/10.1186/scrt377
Bhushan, Abhinav ; Senutovitch, Nina ; Bale, Shyam S. ; McCarty, William J. ; Hegde, Manjunath ; Jindal, Rohit ; Golberg, Inna ; Berk Usta, O. ; Yarmush, Martin L. ; Vernetti, Lawrence ; Gough, Albert ; Bakan, Ahmet ; Shun, Tong Ying ; Biasio, Richard ; Lansing Taylor, D. / Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans. In: Stem Cell Research and Therapy. 2013 ; Vol. 4, No. SUPPL.1.
@article{b1bbf83a2a9b403b8eb13a9c843a4d98,
title = "Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans",
abstract = "Although the process of drug development requires efficacy and toxicity testing in animals prior to human testing, animal models have limited ability to accurately predict human responses to xenobiotics and other insults. Societal pressures are also focusing on reduction of and, ultimately, replacement of animal testing. However, a variety of in vitro models, explored over the last decade, have not been powerful enough to replace animal models. New initiatives sponsored by several US federal agencies seek to address this problem by funding the development of physiologically relevant human organ models on microscopic chips. The eventual goal is to simulate a human-on-a-chip, by interconnecting the organ models, thereby replacing animal testing in drug discovery and development. As part of this initiative, we aim to build a three-dimensional human liver chip that mimics the acinus, the smallest functional unit of the liver, including its oxygen gradient. Our liver-on-a-chip platform will deliver a microfluidic three-dimensional co-culture environment with stable synthetic and enzymatic function for at least 4 weeks. Sentinel cells that contain fluorescent biosensors will be integrated into the chip to provide multiplexed, real-time readouts of key liver functions and pathology. We are also developing a database to manage experimental data and harness external information to interpret the multimodal data and create a predictive platform.",
author = "Abhinav Bhushan and Nina Senutovitch and Bale, {Shyam S.} and McCarty, {William J.} and Manjunath Hegde and Rohit Jindal and Inna Golberg and {Berk Usta}, O. and Yarmush, {Martin L.} and Lawrence Vernetti and Albert Gough and Ahmet Bakan and Shun, {Tong Ying} and Richard Biasio and {Lansing Taylor}, D.",
year = "2013",
month = "12",
day = "20",
doi = "10.1186/scrt377",
language = "English (US)",
volume = "4",
journal = "Stem Cell Research and Therapy",
issn = "1757-6512",
publisher = "BioMed Central",
number = "SUPPL.1",

}

TY - JOUR

T1 - Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans

AU - Bhushan, Abhinav

AU - Senutovitch, Nina

AU - Bale, Shyam S.

AU - McCarty, William J.

AU - Hegde, Manjunath

AU - Jindal, Rohit

AU - Golberg, Inna

AU - Berk Usta, O.

AU - Yarmush, Martin L.

AU - Vernetti, Lawrence

AU - Gough, Albert

AU - Bakan, Ahmet

AU - Shun, Tong Ying

AU - Biasio, Richard

AU - Lansing Taylor, D.

PY - 2013/12/20

Y1 - 2013/12/20

N2 - Although the process of drug development requires efficacy and toxicity testing in animals prior to human testing, animal models have limited ability to accurately predict human responses to xenobiotics and other insults. Societal pressures are also focusing on reduction of and, ultimately, replacement of animal testing. However, a variety of in vitro models, explored over the last decade, have not been powerful enough to replace animal models. New initiatives sponsored by several US federal agencies seek to address this problem by funding the development of physiologically relevant human organ models on microscopic chips. The eventual goal is to simulate a human-on-a-chip, by interconnecting the organ models, thereby replacing animal testing in drug discovery and development. As part of this initiative, we aim to build a three-dimensional human liver chip that mimics the acinus, the smallest functional unit of the liver, including its oxygen gradient. Our liver-on-a-chip platform will deliver a microfluidic three-dimensional co-culture environment with stable synthetic and enzymatic function for at least 4 weeks. Sentinel cells that contain fluorescent biosensors will be integrated into the chip to provide multiplexed, real-time readouts of key liver functions and pathology. We are also developing a database to manage experimental data and harness external information to interpret the multimodal data and create a predictive platform.

AB - Although the process of drug development requires efficacy and toxicity testing in animals prior to human testing, animal models have limited ability to accurately predict human responses to xenobiotics and other insults. Societal pressures are also focusing on reduction of and, ultimately, replacement of animal testing. However, a variety of in vitro models, explored over the last decade, have not been powerful enough to replace animal models. New initiatives sponsored by several US federal agencies seek to address this problem by funding the development of physiologically relevant human organ models on microscopic chips. The eventual goal is to simulate a human-on-a-chip, by interconnecting the organ models, thereby replacing animal testing in drug discovery and development. As part of this initiative, we aim to build a three-dimensional human liver chip that mimics the acinus, the smallest functional unit of the liver, including its oxygen gradient. Our liver-on-a-chip platform will deliver a microfluidic three-dimensional co-culture environment with stable synthetic and enzymatic function for at least 4 weeks. Sentinel cells that contain fluorescent biosensors will be integrated into the chip to provide multiplexed, real-time readouts of key liver functions and pathology. We are also developing a database to manage experimental data and harness external information to interpret the multimodal data and create a predictive platform.

UR - http://www.scopus.com/inward/record.url?scp=84891364200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891364200&partnerID=8YFLogxK

U2 - 10.1186/scrt377

DO - 10.1186/scrt377

M3 - Article

C2 - 24565476

AN - SCOPUS:84891364200

VL - 4

JO - Stem Cell Research and Therapy

JF - Stem Cell Research and Therapy

SN - 1757-6512

IS - SUPPL.1

M1 - S16

ER -